Login / Signup

CYP3A and CYP2C19 Activity Determined by Microdosed Probe Drugs Accurately Predict Voriconazole Clearance in Healthy Adults.

Amin MuharebAntje BlankAndreas Daniel MeidKathrin I FoersterFelicitas StollJuergen BurhenneWalter Emil HaefeliGerd Mikus
Published in: Clinical pharmacokinetics (2023)
TRIAL REGISTRATION: EudraCT No: 2020-001017-20, registered on March 5th, 2020. DRKS: DRKS00022547, registered on August 6th, 2020.
Keyphrases
  • study protocol
  • phase iii
  • clinical trial
  • phase ii
  • living cells
  • quantum dots
  • drug induced
  • fluorescent probe
  • single molecule